Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for MannKind Corporation (MNKD : NSDQ)
 
 • Company Description   
Mannkind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. The Company's lead product, the Technosphere Insulin System, consists of the Company's dry-powder Technosphere formulation of insulin and the Company's MedTone inhaler through which the powder is inhaled into the deep lung.

Number of Employees: 407

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.60 Daily Weekly Monthly
20 Day Moving Average: 3,446,879 shares
Shares Outstanding: 303.93 (millions)
Market Capitalization: $1,094.16 (millions)
Beta: 0.96
52 Week High: $7.63
52 Week Low: $3.52
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -16.28% -20.81%
12 Week -22.41% -34.91%
Year To Date -44.01% -47.56%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1 CASPER STREET
-
DANBURY,CT 06810
USA
ph: 818-661-5000
fax: 661-775-2081
ir@mannkindcorp.com http://www.mannkindcorp.com
 
 • General Corporate Information   
Officers
Michael E. Castagna - Chief Executive Officer and Director
Christopher B. Prentiss - Chief Financial Officer
James S. Shannon - Chairman of the Board of Directors
Steven B. Binder - Director
Ronald J. Consiglio - Director

Peer Information
MannKind Corporation (CORR.)
MannKind Corporation (RSPI)
MannKind Corporation (CGXP)
MannKind Corporation (BGEN)
MannKind Corporation (GTBP)
MannKind Corporation (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 56400P706
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/06/25
Share - Related Items
Shares Outstanding: 303.93
Most Recent Split Date: 3.00 (0.20:1)
Beta: 0.96
Market Capitalization: $1,094.16 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.04 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $0.18 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/06/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 19.64
Trailing 12 Months: 22.50
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: 25.94
Price / Sales: 3.68
EPS Growth
vs. Year Ago Period: 0.00%
vs. Previous Quarter: 33.33%
Sales Growth
vs. Year Ago Period: 18.25%
vs. Previous Quarter: 2.06%
ROE
06/30/25 - -
03/31/25 - -32.41
12/31/24 - -23.91
ROA
06/30/25 - -
03/31/25 - 10.85
12/31/24 - 9.98
Current Ratio
06/30/25 - -
03/31/25 - 2.36
12/31/24 - 3.28
Quick Ratio
06/30/25 - -
03/31/25 - 2.11
12/31/24 - 2.94
Operating Margin
06/30/25 - -
03/31/25 - 15.60
12/31/24 - 15.59
Net Margin
06/30/25 - -
03/31/25 - 10.12
12/31/24 - 9.66
Pre-Tax Margin
06/30/25 - -
03/31/25 - 11.17
12/31/24 - 10.69
Book Value
06/30/25 - -
03/31/25 - -0.19
12/31/24 - -0.29
Inventory Turnover
06/30/25 - -
03/31/25 - 2.79
12/31/24 - 2.90
Debt-to-Equity
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Capital
06/30/25 - -
03/31/25 - -
12/31/24 - -
 

Powered by Zacks Investment Research ©